Equity Profile

BCRX

BIOCRYST PHARMACEUTI

Health CareBiotechnology$2.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $2 billion, its work is crucial in the healthcare sector, particularly in addressing unmet medical needs through its specialized therapies.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In the last quarter, BioCryst reported a significant earnings miss with an EPS of -$2.98, far below the expected $0.06. This disappointing performance led to a 2.21% drop in the stock price the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about the upcoming earnings report, especially after the recent volatility in stock performance. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If BioCryst can demonstrate strong revenue growth and positive updates from clinical trials, it could restore investor confidence and lead to a significant stock rally.

Bear Case

Conversely, another earnings miss or negative trial results could further erode trust in the company's ability to deliver on its promises, leading to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the significant miss last quarter, the EPS figure will be critical in assessing whether the company is on a recovery path.

What updates can management provide on ongoing clinical trials?

Positive developments in clinical trials could greatly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioCryst to recover from its last earnings miss, given the recent positive developments in its clinical pipeline.

Supporting Evidence

The options market is pricing in a 28.46% move, suggesting that traders expect significant volatility, which could indicate a more favorable outlook than currently perceived.

The company's historical EPS beat rate of 63% suggests that it has the potential to surprise positively, despite recent misses.

Key Risk

If the company reports a strong EPS and positive trial updates, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether BioCryst can recover from its recent earnings miss and demonstrate progress in its clinical programs.

Bull Confirmed If

A return to positive EPS, ideally above $0.10, would confirm the bull case and suggest a turnaround in financial performance.

Bear Confirmed If

Another EPS miss, particularly below -$2.00, would reinforce bearish sentiment and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings release.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential stock increase of around 7.73%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management commentary.

Miss

A miss could lead to a decline of approximately 8.34%, reflecting ongoing concerns about the company's performance and future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials and potential timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for BioCryst's products and any new partnerships.
4Any changes in guidance or expectations for the upcoming quarters.
5Discussion on competitive landscape and how BioCryst plans to position itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioCryst can demonstrate strong revenue growth and positive updates from clinical trials, it could restore investor confidence and lead to a significant stock rally.

Bear Case

Conversely, another earnings miss or negative trial results could further erode trust in the company's ability to deliver on its promises, leading to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the significant miss last quarter, the EPS figure will be critical in assessing whether the company is on a recovery path.

What updates can management provide on ongoing clinical trials?

Positive developments in clinical trials could greatly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioCryst to recover from its last earnings miss, given the recent positive developments in its clinical pipeline.

Supporting Evidence

The options market is pricing in a 28.46% move, suggesting that traders expect significant volatility, which could indicate a more favorable outlook than currently perceived.

The company's historical EPS beat rate of 63% suggests that it has the potential to surprise positively, despite recent misses.

Key Risk

If the company reports a strong EPS and positive trial updates, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether BioCryst can recover from its recent earnings miss and demonstrate progress in its clinical programs.

Bull Confirmed If

A return to positive EPS, ideally above $0.10, would confirm the bull case and suggest a turnaround in financial performance.

Bear Confirmed If

Another EPS miss, particularly below -$2.00, would reinforce bearish sentiment and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings release.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential stock increase of around 7.73%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management commentary.

Miss

A miss could lead to a decline of approximately 8.34%, reflecting ongoing concerns about the company's performance and future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials and potential timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for BioCryst's products and any new partnerships.
4Any changes in guidance or expectations for the upcoming quarters.
5Discussion on competitive landscape and how BioCryst plans to position itself.